Illumina upgraded to Overweight from Neutral at Piper Jaffray Piper Jaffray upgraded Illumina after its channel checks indicated the company is experiencing next-gen sequencing share gains. The firm raised its price target for shares to $61 from $47.
News For ILMN From The Last 14 Days
Check below for free stories on ILMN the last two weeks.
WuXi PharmaTech purchases Illumina HiSeq X Ten Sequencing System Illumina (LMN) and WuXi PharmaTech (WX) announced that the WuXi Genome Center has purchased an Illumina HiSeq X Ten sequencing system. This new investment will enable WuXi’s clinical genomic services to expand from the current target panel, exome, and transcriptome scale sequencing to population genome scale sequencing. It puts the world’s most advanced gene sequencing capability in the hands of the leading pharmaceutical R&D services company in the Asia Pacific region. The WuXi Genome Center meets international clinical standards and is the only CLIA-certified clinical genomics lab in China. In addition to offering sequencing services, WuXi’s genomics lab also provides assay development, validation, and testing services.